Coenzyme I and Chronic Fatigue Syndrome

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating and chronic multisystem illness with an unknown etiology. Immune dysfunction, energy metabolism and mitochondrial abnormalities, and chronic neuroinflammation have been recognized as crucial key pathogenesis in the perpetuation of ME/CFS. Nicotinamide adenine dinucleotide (NADH), a reduced form of coenzyme I, with the properties of enhancing mitochondrial function as a bioenergy cofactor, scavenging free radicals, and antioxidant, is considered a candidate drug for the treatment of CFS. Several clinical trials have demonstrated the potential for NADH to improve symptoms in patients with CFS. CoQ10 and NADH combined supplementation may be a better safer treatment option for CFS.